Burkitt's lymphoma laboratory tests: Difference between revisions
Jump to navigation
Jump to search
Kamal Akbar (talk | contribs) No edit summary |
Kamal Akbar (talk | contribs) No edit summary |
||
| Line 15: | Line 15: | ||
* [[Cytogenetics]] include: | * [[Cytogenetics]] include: | ||
:* Giemsa banding | :* Giemsa banding | ||
:* Fluorescence in situ hybridization ([[FISH]]) | :* Fluorescence in situ hybridization ([[FISH]])<ref name="GrygalewiczWoroniecka2018">{{cite journal|last1=Grygalewicz|first1=Beata|last2=Woroniecka|first2=Renata|last3=Rymkiewicz|first3=Grzegorz|last4=Rygier|first4=Jolanta|last5=Borkowska|first5=Klaudia|last6=Kotyl|first6=Aleksandra|last7=Blachnio|first7=Katarzyna|last8=Bystydzienski|first8=Zbigniew|last9=Nowakowska|first9=Beata|last10=Pienkowska-Grela|first10=Barbara|title=The 11q-Gain/Loss Aberration Occurs Recurrently in MYC-Negative Burkitt-like Lymphoma With 11q Aberration, as Well as MYC-Positive Burkitt Lymphoma and MYC-Positive High-Grade B-Cell Lymphoma, NOS|journal=American Journal of Clinical Pathology|volume=149|issue=1|year=2018|pages=17–28|issn=0002-9173|doi=10.1093/ajcp/aqx139}}</ref> | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 21:46, 4 January 2019
|
Burkitt's lymphoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Burkitt's lymphoma laboratory tests On the Web |
|
American Roentgen Ray Society Images of Burkitt's lymphoma laboratory tests |
|
Risk calculators and risk factors for Burkitt's lymphoma laboratory tests |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
Laboratory tests for Burkitt's lymphoma include complete blood count (CBC), blood chemistry studies, immuno histochemistry, HIV blood test, flow cytometric analysis, and cytogenetics.
Laboratory Findings
Laboratory tests for Burkitt's lymphoma include:[1]
- Complete blood count[2]
- Blood chemistry studies include:
- HIV blood test [4]
- Immuno histochemistry: CD19 +, CD20 +, CD22 +, CD79a +, Bcl-6 +, CD10 +, CD38 +, Mum-1 -, CD44 -, CD138 -, and Bcl-2-[5]
- Flow cytometric analysis: (immunophenotype) CD19 +, CD20 +, CD22 +, and cytoplasmic terminal deoxynucleotidyl transferase (TdT) -[6]
- Cytogenetics include:
References
- ↑ Perkins AS, Friedberg JW (2008). "Burkitt lymphoma in adults". Hematology Am Soc Hematol Educ Program: 341–8. doi:10.1182/asheducation-2008.1.341. PMID 19074108.
- ↑ Ekemen S, Uzay A, Bassullu N, Dikicioglu-Cetin E, Matsuda K, Ince U; et al. (2018). "Does it take three to tango? An unsuspected multimorbidity of CD8+ T cell lymphoproliferative disorder, malaria, and EBV infection". Malar J. 17 (1): 349. doi:10.1186/s12936-018-2497-9. PMC 6173833. PMID 30290813.
- ↑ 3.0 3.1 Mwanda WO, Orem J, Remick SC, Rochford R, Whalen C, Wilson ML (2005). "Clinical characteristics of Burkitt's lymphoma from three regions in Kenya". East Afr Med J. 82 (9 Suppl): S135–43. PMID 16619689.
- ↑ Pinisetti S, Nalabolu GR, Uvr C, Tadi DP (2013). "HIV Associated Intra-oral Burkitt's Lymphoma: A Case Report". J Clin Diagn Res. 7 (12): 3088–9. doi:10.7860/JCDR/2013/6715.3862. PMC 3919292. PMID 24551737.
- ↑ Kretzmer H, Bernhart SH, Wang W, Haake A, Weniger MA, Bergmann AK; et al. (2015). "DNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control". Nat Genet. 47 (11): 1316–1325. doi:10.1038/ng.3413. PMC 5444523. PMID 26437030.
- ↑ McGowan P, Nelles N, Wimmer J, Williams D, Wen J, Li M; et al. (2012). "Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: the role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system". Am J Clin Pathol. 137 (4): 665–70. doi:10.1309/AJCP3FEPX5BEEKGX. PMC 4975158. PMID 22431545.
- ↑ Grygalewicz, Beata; Woroniecka, Renata; Rymkiewicz, Grzegorz; Rygier, Jolanta; Borkowska, Klaudia; Kotyl, Aleksandra; Blachnio, Katarzyna; Bystydzienski, Zbigniew; Nowakowska, Beata; Pienkowska-Grela, Barbara (2018). "The 11q-Gain/Loss Aberration Occurs Recurrently in MYC-Negative Burkitt-like Lymphoma With 11q Aberration, as Well as MYC-Positive Burkitt Lymphoma and MYC-Positive High-Grade B-Cell Lymphoma, NOS". American Journal of Clinical Pathology. 149 (1): 17–28. doi:10.1093/ajcp/aqx139. ISSN 0002-9173.